Endocrine gland‑derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells

Ren,Linan; Guo,Xiaozhong; Shao,Xiaodong; Li,Hongyu; Yao,Hui

doi:10.3892/mmr.2015.3340

Endocrine gland‑derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells

Authors:
- Linan Ren
- Xiaozhong Guo
- Xiaodong Shao
- Hongyu Li
- Hui Yao
View Affiliations

Affiliations: Department of Gastroenterology, Shenyang General Hospital of PLA, Shenyang, Liaoning 110840, P.R. China
Published online on: February 12, 2015 https://doi.org/10.3892/mmr.2015.3340
Pages: 4279-4284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endocrine gland‑derived vascular endothelial growth factor (EG‑VEGF) is a newly cloned factor that selectively acts on the endothelium of endocrine gland cells. EG‑VEGF was previously identified as an important cytokine, involved in the modulation of apoptosis in pancreatic cancer cell lines. The present study examined the effects of EG‑VEGF proliferation and migration, in pancreatic cancer cells. To determine the potential for EG‑VEGF as a therapeutic target for pancreatic cancer, the expression of EG‑VEGF were measured in pancreatic cancer tissue, and the association between its expression and the clinicopathological characteristics of the pancreatic cancer patients was determined. The results of the present study suggest that EG‑VEGF may act as a novel tumor gene in pancreatic cancer. EG‑VEGF was rarely expressed in the normal pancreatic tissue, but was highly expressed in the pancreatic cancer tissue. These data suggest that EG‑VEGF may be a cancer‑specific, and possibly tissue‑specific, survival factor in the pancreas. In the Mia PaCa‑2 pancreatic cancer cell line, EG‑VEGF was shown to promote proliferation and cellular invasion, and modulate the phosphorylation of mitogen‑activated protein kinase, a modulator for the malignant phenotype.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
2	Wolfgang CL, Herman JM, Laheru DA, et al: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
3	LeCouter J, Kowalski J, Foster J, et al: Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 412:877–884. 2001. View Article : Google Scholar : PubMed/NCBI
4	Monnier J and Samson M: Cytokine properties of prokineticins. FEBS J. 275:4014–4021. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ren LN, Li QF, Xiao FJ, et al: Endocrine glands-derived vascular endothelial growth factor protects pancreatic cancer cells from apoptosis via upregulation of the myeloid cell leukemia-1 protein. Biochem Biophys Res Commun. 386:35–39. 2009. View Article : Google Scholar : PubMed/NCBI
6	Bosman FT: WHO Classification of Tumours of the Digestive System. 4th. IARC Press; Lyon: 2010
7	Song JW and Lee JH: New morphological features for grading pancreatic ductal adenocarcinomas. Biomed Res Int. 2013:1752712013. View Article : Google Scholar : PubMed/NCBI
8	Nagano H, Goi T, Koneri K, et al: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer. J Surg Oncol. 96:605–610. 2007. View Article : Google Scholar : PubMed/NCBI
9	LeCouter J, Lin R, Tejada M, et al: The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci USA. 100:2685–2690. 2003. View Article : Google Scholar : PubMed/NCBI
10	Kisliouk T, Levy N, Hurwitz A and Meidan R: Presence and regulation of endocrine gland vascular endothelial growth factor/prokineticin-1 and its receptors in ovarian cells. J Clin Endocrinol Metab. 88:3700–3707. 2003. View Article : Google Scholar : PubMed/NCBI
11	Morales A, Vilchis F, Chávez B, et al: Expression and localization of endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in human pancreas and pancreatic adenocarcinoma. J Steroid Biochem Mol Biol. 107:37–41. 2007. View Article : Google Scholar : PubMed/NCBI
12	Rini BI: Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer. 115:2306–2312. 2009. View Article : Google Scholar : PubMed/NCBI
13	Jiang X, Abiatari I, Kong B, et al: Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer. Pancreatology. 9:165–172. 2009. View Article : Google Scholar
14	Morales A, Morimoto S, Díaz L, Robles G and Díaz-Sánchez V: Endocrine gland-derived vascular endothelial growth factor in rat pancreas: genetic expression and testosterone regulation. J Endocrinol. 197:309–314. 2008. View Article : Google Scholar : PubMed/NCBI
15	Dingli D, Chalub FA, Santos FC, Van Segbroeck S and Pacheco JM: Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br J Cancer. 101:1130–1136. 2009. View Article : Google Scholar : PubMed/NCBI
16	Stasinopoulos I, Mori N and Bhujwalla ZM: The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. Neoplasia. 10:1163–1169. 2008.PubMed/NCBI
17	Nielsen JD, Moeslund M, Wandall HH and Dabelsteen S: Influences of tumor stroma on the malignant phenotype. J Oral Pathol Med. 37:412–416. 2008. View Article : Google Scholar : PubMed/NCBI
18	Melnikova VO and Bar-Eli M: Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther. 7:997–1003. 2008. View Article : Google Scholar : PubMed/NCBI
19	Grzesiak JJ and Bouvet M: Divalent cations modulate the integrin-mediated malignant phenotype in pancreatic cancer cells. Cancer Sci. 99:1553–1563. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ngan ES, Sit FY, Lee K, et al: Implications of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 signaling in human neuroblastoma progression. Clin Cancer Res. 13:868–875. 2007. View Article : Google Scholar : PubMed/NCBI
21	Koul HK, Pal M and Koul S: Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
22	Arlt A, Müerköster SS and Schäfer H: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 332:346–358. 2013. View Article : Google Scholar
23	Bayraktar S and Rocha-Lima CM: Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med. 77:606–619. 2010. View Article : Google Scholar : PubMed/NCBI
24	Labasque M, Reiter E, Becamel C, et al: Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. Mol Biol Cell. 19:4640–4650. 2008. View Article : Google Scholar : PubMed/NCBI